Distribution deals include Streuli Pharma in Switzerland; Plac Control in Greece; PharmaPal Drugstore in the United Arab Emirates and George Petrou in Cyprus.
In Germany, Sunstar relaunched the Lactobacillus reuteri Prodentis-based products.
“With the rapidly increasing body of clinical proof for Lactobacillus reuteri Prodentis and the strong interest in the products among international distribution partners, we are confident that the oral health area will become an important part of our business,” said CEO and president, Peter Rothschild.
The products are available in 20 countries and come in lozenges and gums for consumers and oil drops for health professionals.
BioGaia recorded sales of €25.74m for the first nine months of 2013, up 4% on the corresponding 2012 period.
See a company interview with Rothschild discussing the figures here.
<iframe width="610" height="343" src="//www.youtube.com/embed/OxuhNoQbMUE?list=UUTrKBxuApr3XY0wk0WgRk0g" frameborder="0" allowfullscreen></iframe>
In June BioGaia paid €3.5m to take 100% control of probiotic drop producer TwoPac. It previously had a 50% stake in the 11-year-old fellow Swedish firm.
TwoPac’s only client is BioGaia, which funded a new factory it built in 2012.
“The most important aspect of the acquisition is that it will give us unlimited access to TwoPac’s product development capacity and expertise in building customised machinery,” said Rothschild at the time.
Invested in pre- and probiotics? Probiota 2014 will explore the prebiotic-probiotic scientific frontier, its evolution and commercial application in food, nutraceuticals, pharmaceuticals and cosmetics across the globe.
The 2-day, 2-stream event – formerly Probiotech and Microbiota - will be held in Amsterdam on February 4-5 next year. Will you be joining your peers there?
More information here.